LKFT · Nasdaq, OTC · CIK 0001421876

Lakefront Biotherapeutics NV

Lakefront Biotherapeutics NV’s most recent SEC filing in our snapshot is a Form 6-K filed on Oct 20, 2026. In fiscal 2025 (year ended Dec 31, 2025) it reported revenue of EUR 1.1B and net income of EUR 320.9M, according to its XBRL data on EDGAR. Its EDGAR record lists 0 Form 4 insider filings from the 12 months before our last refresh.

SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.

Revenue, FY2025
EUR 1.1B
Net income, FY2025
EUR 320.9M
Form 4 filings on record, past 12 months
0

Company overview

Legal name (as filed)
Lakefront Biotherapeutics NV
Tickers
LKFT, GLPGF
SEC Central Index Key (CIK)
0001421876
Industry (SIC)
Pharmaceutical Preparations (code 2834)
Business address
2800 MECHELEN
State or country of incorporation
Belgium
Fiscal year ends
—
SEC filer category
Large accelerated filer
Position in SEC ticker list
#1956 of the 3,000 companies we track

Five-year financial highlights

Full-year figures from Lakefront Biotherapeutics NV’s annual reports, as tagged in XBRL and published by the SEC. Amounts are in EUR; the fiscal year is named for the calendar year in which it ends.

Revenue
EUR 234.4MFY2021EUR 241.2MFY2022EUR 239.7MFY2023EUR 275.6MFY2024EUR 1.1BFY2025
Net income
-EUR 103.2MFY2021-EUR 218.0MFY2022EUR 211.7MFY2023EUR 74.1MFY2024EUR 320.9MFY2025
LKFT annual results
ItemFY2021
ended Dec 31, 2021		FY2022
ended Dec 31, 2022		FY2023
ended Dec 31, 2023		FY2024
ended Dec 31, 2024		FY2025
ended Dec 31, 2025
RevenueEUR 234.4MEUR 241.2MEUR 239.7MEUR 275.6MEUR 1.1B
Net income-EUR 103.2M-EUR 218.0MEUR 211.7MEUR 74.1MEUR 320.9M
Diluted EPS-EUR 1.58-EUR 3.32EUR 3.21EUR 1.12EUR 4.87
Total assetsEUR 5.2BEUR 4.7BEUR 4.4BEUR 4.1BEUR 3.4B
Cash and equivalentsEUR 2.2BEUR 508.1MEUR 166.8MEUR 64.2MEUR 87.9M

XBRL tags used: revenue = Revenue; netIncome = ProfitLoss; assets = Assets; eps = DilutedEarningsLossPerShare; cash = CashAndCashEquivalents. EPS is shown as originally reported for each year and may not be adjusted for later stock splits. A dash means the company did not report that item in a form we could match.

How to read these numbers

Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.

Latest key reports

The most recent filing of each major report type, even if it falls outside the 40 newest filings below.

LKFT latest annual, quarterly, current and proxy reports
FiledFormWhat it isOriginal
Mar 26, 202620-FAnnual report of a foreign private issuer· period Dec 31, 2025Document · Index
Oct 20, 20266-KReport of a foreign private issuer· period Oct 20, 2026Document · Index

Recent SEC filings

The 40 newest documents filed by or about Lakefront Biotherapeutics NV, by form type:

6-K ×37SCHEDULE 13G ×1424B3 ×120-F ×1
LKFT recent filings
FiledFormWhat it isOriginal
Oct 20, 20266-KReport of a foreign private issuer· period Oct 20, 2026Document · Index
Oct 15, 20266-KReport of a foreign private issuer· period Oct 14, 2026Document · Index
Oct 13, 20266-KReport of a foreign private issuer· period Oct 13, 2026Document · Index
Oct 9, 20266-KReport of a foreign private issuer· period Oct 8, 2026Document · Index
Oct 6, 20266-KReport of a foreign private issuer· period Oct 6, 2026Document · Index
Sep 29, 20266-KReport of a foreign private issuer· period Sep 29, 2026Document · Index
Sep 23, 20266-KReport of a foreign private issuer· period Sep 22, 2026Document · Index
Sep 15, 20266-KReport of a foreign private issuer· period Sep 15, 2026Document · Index
Sep 8, 20266-KReport of a foreign private issuer· period Sep 8, 2026Document · Index
Sep 8, 20266-KReport of a foreign private issuer· period Sep 8, 2026Document · Index
Sep 1, 20266-KReport of a foreign private issuer· period Sep 1, 2026Document · Index
Aug 25, 20266-KReport of a foreign private issuer· period Aug 25, 2026Document · Index
Aug 25, 20266-KReport of a foreign private issuer· period Aug 25, 2026Document · Index
Aug 25, 20266-KReport of a foreign private issuer· period Aug 25, 2026Document · Index
Aug 18, 20266-KReport of a foreign private issuer· period Aug 18, 2026Document · Index
Aug 12, 20266-KReport of a foreign private issuer· period Aug 12, 2026Document · Index
Aug 12, 20266-KReport of a foreign private issuer· period Aug 12, 2026Document · Index
Aug 4, 20266-KReport of a foreign private issuer· period Aug 4, 2026Document · Index
Jul 28, 20266-KReport of a foreign private issuer· period Jul 28, 2026Document · Index
Jul 21, 20266-KReport of a foreign private issuer· period Jul 21, 2026Document · Index
Jul 15, 20266-KReport of a foreign private issuer· period Jul 14, 2026Document · Index
Jul 13, 20266-KReport of a foreign private issuer· period Jul 13, 2026Document · Index
Jul 7, 20266-KReport of a foreign private issuer· period Jul 7, 2026Document · Index
Jun 30, 20266-KReport of a foreign private issuer· period Jun 30, 2026Document · Index
Jun 30, 20266-KReport of a foreign private issuer· period Jun 29, 2026Document · Index
Jun 24, 20266-KReport of a foreign private issuer· period Jun 23, 2026Document · Index
Jun 23, 2026SCHEDULE 13GPassive beneficial ownership report (over 5%)Document · Index
Jun 16, 20266-KReport of a foreign private issuer· period Jun 16, 2026Document · Index
Jun 9, 20266-KReport of a foreign private issuer· period Jun 9, 2026Document · Index
Jun 9, 20266-KReport of a foreign private issuer· period Jun 8, 2026Document · Index
Jun 5, 20266-KReport of a foreign private issuer· period Jun 4, 2026Document · Index
May 27, 20266-KReport of a foreign private issuer· period May 26, 2026Document · Index
May 8, 2026424B3424B3Document · Index
May 6, 20266-KReport of a foreign private issuer· period May 6, 2026Document · Index
Apr 29, 20266-KReport of a foreign private issuer· period Apr 28, 2026Document · Index
Mar 31, 20266-KReport of a foreign private issuer· period Mar 31, 2026Document · Index
Mar 30, 20266-KReport of a foreign private issuer· period Mar 30, 2026Document · Index
Mar 26, 202620-FAnnual report of a foreign private issuer· period Dec 31, 2025Document · Index
Mar 24, 20266-KReport of a foreign private issuer· period Mar 23, 2026Document · Index
Mar 17, 20266-KReport of a foreign private issuer· period Mar 17, 2026Document · Index

Insider filing activity

0 Form 4 filings appear in Lakefront Biotherapeutics NV’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.

Other companies in Pharmaceutical Preparations

All 194 companies in Pharmaceutical Preparations

On Amazon

Popular tools for investors

As an Amazon Associate I earn from qualifying purchases.

Electronics Plaud Note Pro AI Voice Recorder An AI voice recorder that turns earnings calls and meetings into notes. View on Amazon → Electronics Amazon Kindle Paperwhite Signature Edition 32GB Read investing classics and long reports without eye strain. View on Amazon → Electronics Apple 2026 MacBook Air 13-inch Laptop A lightweight laptop for spreadsheets and filing research. View on Amazon →

Source

  • U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0001421876 and XBRL company facts. Lakefront Biotherapeutics NV on EDGAR.
  • Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.

Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.